[시장보고서]주의력결핍 과잉행동장애(ADHD) 치료제 시장 : 세계 산업 분석, 시장 규모, 점유율, 성장, 동향, 예측(2025-2032년)

주의력결핍 과잉행동장애(ADHD) 치료제 시장 : 세계 산업 분석, 시장 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Attention Deficit Hyperactivity Disorder Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

상품코드 : 1684478

리서치사 : Persistence Market Research

발행일 : 2025년 03월

페이지 정보 : 영문 250 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,227,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,555,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 12,291,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

Persistence Market Research는 최근 세계 주의력결핍 과잉행동장애(ADHD) 치료제 시장에 대한 상세한 분석을 발표하고 시장 성장 촉진요인, 동향, 기회, 과제 등 주요 시장 역학에 대한 상세한 평가를 제공한다고 밝혔습니다. 이 보고서는 2025년부터 2032년까지 ADHD 치료제 시장 예측 성장 궤적을 개괄하는 독점 데이터와 통계적 통찰력을 제공합니다.

주요 인사이트

주의력결핍 과잉행동장애(ADHD) 치료제 시장 규모(2025년) : 153억 달러
시장 규모 예측(금액 기준, 2032년) : 4,310만 달러
세계 시장 성장률(CAGR, 2025-2032년) : 15.9%

주의력결핍 과잉행동장애(ADHD) 치료제 시장 : 분석 범위

주의력결핍 과잉행동장애(ADHD)는 일반적으로 소아에서 진단되며 성인기까지 지속되는 신경발달장애로, ADHD 치료제 시장은 부주의, 충동성, 과잉행동 등의 증상을 관리하기 위한 약리학적 치료와 비약리학적 치료로 구성됩니다. 이 시장은 소아, 청소년, 성인 등 다양한 환자군을 대상으로 하며, 치료 옵션은 자극제, 비자극제, 행동치료에 이르기까지 다양하며, ADHD에 대한 인식이 높아지면서 치료 옵션의 발전과 조기 진단을 위한 노력과 함께 시장 확대의 원동력이 되고 있습니다. 또한, ADHD 유병률 증가와 ADHD 관리를 위한 원격 의료 서비스의 채택 증가는 시장 성장에 영향을 미치는 주요 요인입니다.

시장 성장 촉진요인:

세계 ADHD 치료제 시장은 주로 다양한 연령대에서 ADHD 유병률 증가에 힘입어 성장하고 있습니다. 특히 선진국에서의 인식 개선과 진단 능력의 향상이 치료율 향상에 기여하고 있습니다. 또한, 서방형 약물과 새로운 비자극성 치료제를 포함한 약물 제제의 발전은 치료 효과와 환자 순응도를 높이고 있으며, 디지털 헬스 플랫폼과 원격 의료가 ADHD 진료에 도입되면서 치료 접근성이 더욱 확대되고 있습니다. 또한, 개인 맞춤형 의료와 ADHD에 영향을 미치는 유전적 요인에 대한 연구는 향후 치료 접근 방식에 혁명을 가져올 것으로 기대되고 있습니다.

시장 성장 억제요인:

ADHD 치료제 시장은 큰 성장 잠재력에도 불구하고 불면증, 식욕부진, 심혈관계 위험 등 자극제 부작용에 대한 우려와 같은 문제에 직면해 있습니다. 또한, 신약 승인을 위한 규제 장벽과 엄격한 처방 가이드라인은 시장 확대를 제한할 수 있으며, ADHD 치료제, 특히 장기 치료제의 높은 가격은 특히 중저소득 국가에서 구매하기 쉬운 가격인지에 대한 의문이 제기되고 있습니다. 또한, 특정 지역에서는 사회적 편견과 과소진단이 치료 도입의 장벽으로 작용하고 있습니다.

시장 기회:

ADHD 치료제 시장은 약물 제제의 기술 혁신과 대체 치료 접근법으로 인해 큰 비즈니스 기회를 창출하고 있습니다. 인지행동치료(CBT), 뉴로피드백, 식이요법 등 비자극적 치료는 보완적 치료 또는 단독 치료로 각광받고 있습니다. 유전적, 신경생물학적 요인에 대한 연구가 확대되면서 환자 개개인의 필요에 맞춘 정밀의료의 길이 열리고 있습니다. 또한, ADHD 진단 및 치료 모니터링에서 인공지능(AI)의 역할이 증가함에 따라 의료 서비스 제공업체 및 제약사에게 새로운 성장의 길을 제공합니다. 또한, 시장 기업들은 디지털 헬스 플랫폼과 원격 의료 솔루션을 통해 약물 개발을 강화하고 환자 접근성을 개선하기 위한 전략적 제휴를 모색하고 있습니다.

본 보고서에서 답변을 얻을 수 있는 주요 질문

ADHD 치료제 시장의 세계 성장을 가속하는 주요 요인은?
기술의 발전은 ADHD 치료의 미래를 어떻게 형성하고 있는가?
시장 확대에 영향을 미치는 주요 과제와 억제요인은 무엇인가?
ADHD 치료제 시장의 주요 기업은? 경쟁 우위를 점하기 위해 어떤 전략을 실행하고 있는가?
ADHD 치료제 시장의 새로운 트렌드와 투자 기회는?

서론/주요 조사 결과
과거 시장 규모 분석 : 약제별(10억 달러, 2019-2024년)
현재 시장 규모 분석과 예측 : 약제별(10억 달러, 2025-2032년)
- 각성제
  - Amphetamine
  - Methylphenidate
  - Dextroamphetamine
  - Dexmethylphenidate
  - Lisdexamfetamine Dimesylate
- 비자극성 물질
  - Atomoxetine
  - Bupropion
  - Guanfacine
  - Clonidine
시장 매력 분석 : 약제별

제9장 세계의 ADHD 치료제 시장 전망 : 연령층별(2019년-2032년)

서론/주요 조사 결과
과거 시장 규모 분석 : 연령층별(10억 달러, 2019-2024년)
현재 시장 규모 분석과 예측 : 연령층별(10억 달러, 2025-2032년)
- 소아 및 청년
- 성인
시장 매력 분석 : 연령층별

제10장 세계의 ADHD 치료제 시장 전망 : 유통 채널별(2019년-2032년)

서론/주요 조사 결과
과거 시장 규모 분석 : 유통 채널별(10억 달러, 2019-2024년)
현재 시장 규모 분석과 예측 : 유통 채널별(10억 달러, 2025-2032년)
- 전문 클리닉
- 병원 약국
- 소매 약국
- E-Commerce
시장 매력 분석 : 유통 채널별

제11장 세계의 ADHD 치료제 시장 전망 : 지역별(2019년-2032년)

서론
과거 시장 규모 분석 : 지역별(10억 달러, 2019-2024년)
현재 시장 규모 분석과 예측 : 지역별(10억 달러, 2025-2032년)
- 북미
- 라틴아메리카
- 유럽
- 동아시아
- 남아시아
- 오세아니아
- 중동 및 아프리카(MEA)
시장 매력 분석 : 지역별

제12장 북미의 ADHD 치료제 시장 전망(2019-2032년)

제13장 라틴아메리카의 ADHD 치료제 시장 전망(2019-2032년)

제14장 유럽의 ADHD 치료제 시장 전망(2019-2032년)

제15장 동아시아의 ADHD 치료제 시장 전망(2019-2032년)

제16장 남아시아의 ADHD 치료제 시장 전망(2019-2032년)

제17장 오세아니아의 ADHD 치료제 시장 전망(2019-2032년)

제18장 중동 및 아프리카(MEA)의 ADHD 치료제 시장 전망(2019-2032년)

제19장 시장 구조 분석

기업 Tier별 시장 분석
주요 기업의 시장 점유율 분석
시장 입지 분석

제20장 경쟁 분석

경쟁 대시보드
경쟁 벤치마킹
경쟁 상세
- Pfizer Inc.
- Eli Lilly and Company
- Novartis AG
- GlaxoSmithKline PLC
- Mallinckrodt Pharmaceuticals
- Hisamitsu Pharmaceutical Co., Inc.
- Johnson &Johnson
- UCB SA
- Purdue Pharma LP

제21장 사용된 전제조건과 두자어

제22장 조사 방법

LSH

영문 목차

영문목차

Persistence Market Research has recently published an in-depth analysis of the global Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market, providing a detailed evaluation of key market dynamics, including drivers, trends, opportunities, and challenges. The report delivers exclusive data and statistical insights outlining the projected growth trajectory of the ADHD therapeutics market from 2025 to 2032.

Key Insights:

Attention Deficit Hyperactivity Disorder Therapeutics Market Size (2025E):US$ 15.3 Bn
Projected Market Value (2032F): US$ 43.1 Mn
Global Market Growth Rate (CAGR 2025 to 2032): 15.9%

ADHD Therapeutics Market - Report Scope

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder commonly diagnosed in children and often persisting into adulthood. The ADHD therapeutics market comprises pharmacological and non-pharmacological treatments aimed at managing symptoms such as inattention, impulsivity, and hyperactivity. The market serves a diverse patient population, including children, adolescents, and adults, with treatment options ranging from stimulant and non-stimulant medications to behavioral therapies. The increasing awareness of ADHD, coupled with advancements in treatment options and early diagnosis initiatives, is driving market expansion. Additionally, the growing prevalence of ADHD and rising adoption of telehealth services for ADHD management are key factors influencing market growth.

Market Growth Drivers

The global ADHD therapeutics market is primarily driven by the rising prevalence of ADHD across different age groups. Increased awareness and better diagnostic capabilities, particularly in developed regions, are contributing to higher treatment rates. Additionally, advancements in drug formulations, including extended-release medications and novel non-stimulant therapies, are enhancing treatment efficacy and patient compliance. The increasing adoption of digital health platforms and telemedicine for ADHD consultations is further expanding access to treatment. Moreover, research into personalized medicine and genetic factors influencing ADHD is expected to revolutionize future therapeutic approaches.

Market Restraints

Despite strong growth potential, the ADHD therapeutics market faces challenges such as concerns regarding the side effects of stimulant medications, which can include insomnia, decreased appetite, and cardiovascular risks. Additionally, regulatory hurdles for new drug approvals and stringent prescription guidelines can limit market expansion. The high cost of ADHD medications, particularly for long-term treatment, poses a challenge for affordability, especially in low- and middle-income countries. Furthermore, social stigma and underdiagnosis in certain regions act as barriers to treatment adoption.

Market Opportunities

The ADHD therapeutics market presents significant opportunities driven by innovation in drug formulations and alternative treatment approaches. Non-stimulant therapies, including cognitive behavioral therapy (CBT), neurofeedback, and dietary interventions, are gaining traction as complementary or standalone treatments. Expanding research into genetic and neurobiological factors is paving the way for precision medicine approaches tailored to individual patient needs. Additionally, the increasing role of artificial intelligence (AI) in ADHD diagnosis and treatment monitoring offers new growth avenues for healthcare providers and pharmaceutical companies. Market players are also exploring strategic collaborations to enhance drug development and improve patient access through digital health platforms and telemedicine solutions.

Key Questions Answered in the Report:

What are the primary factors driving the growth of the ADHD therapeutics market globally?
How are technological advancements shaping the future of ADHD treatment?
What are the major challenges and restraints impacting market expansion?
Who are the key players in the ADHD therapeutics market, and what strategies are they implementing to gain a competitive edge?
What are the emerging trends and investment opportunities in the ADHD therapeutics market?

Competitive Intelligence and Business Strategy

Leading companies in the global ADHD therapeutics market, including Johnson & Johnson, Eli Lilly and Company, Novartis AG, and Takeda Pharmaceutical Company, are focusing on innovation, strategic partnerships, and product portfolio expansion. These companies are investing in research and development (R&D) to introduce novel drug formulations with improved efficacy and fewer side effects. Mergers, acquisitions, and collaborations with healthcare providers and telemedicine platforms are further enhancing market penetration. Additionally, pharmaceutical firms are emphasizing patient awareness campaigns and educational programs to promote early diagnosis and treatment adherence.

Key Companies Profiled:

Pfizer Inc.
Eli Lilly and Company
Novartis AG
GlaxoSmithKline PLC
Mallinckrodt Pharmaceuticals
Hisamitsu Pharmaceutical Co., Inc.
Johnson & Johnson
UCB S.A.
Purdue Pharma L.P.

Key Segments Covered in Attention Deficit Hyperactivity Disorder Therapeutics Industry Research

Drug:

Stimulants
Amphetamine
Methylphenidate
Dextroamphetamine
Dexmethylphenidate
Lisdexamfetamine Dimesylate
Non-stimulants
Atomoxetine
Bupropion
Guanfacine
Clonidine

Age Group:

Pediatric and Adolescent
Adults

Distribution Channel:

Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-Commerce

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Market Innovation / Development Trends

4. Key Success Factors

4.1. Drug Adoption/Usage Analysis
4.2. Disease Epidemiology
4.3. Reimbursement Scenario
4.4. Pipeline Analysis
4.5. Value Chain Analysis
4.6. Key Regulatory Scenario
4.7. PESTEL Analysis
4.8. Porter's Analysis

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Outlook
- 5.1.3. Global Neurological Disorder Drugs Market Overview
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Impact of Lifestyle on Disease Progression
- 5.2.2. Rising Awareness on Neurological and Neuropsychiatric Disorders
- 5.2.3. Growing Disease Prevalence Globally
- 5.2.4. Rising R&D Efforts for Novel Drug Development
- 5.2.5. Availability of Treatment Modalities
- 5.2.6. Established Genetic Impact on the Etiology of ADHD
- 5.2.7. Cost of Treatment
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

6.1. COVID-19 and Impact Analysis
- 6.1.1. By Drug
- 6.1.2. By Age Group
- 6.1.3. By Distribution Channel
- 6.1.4. By Country
6.2. 2022 Market Scenario

7. Global Attention Deficit Hyperactivity Disorder Therapeutics Market Demand (in Value or Size in US$ Bn) Analysis 2019-2024 and Forecast, 2025-2032

7.1. Historical Market Value (US$ Bn) Analysis, 2019-2024
7.2. Current and Future Market Value (US$ Bn) Projections, 2025-2032
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032, By Drug

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis By Drug, 2019-2024
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug, 2025-2032
- 8.3.1. Stimulants
  - 8.3.1.1. Amphetamine
  - 8.3.1.2. Methylphenidate
  - 8.3.1.3. Dextroamphetamine
  - 8.3.1.4. Dexmethylphenidate
  - 8.3.1.5. Lisdexamfetamine Dimesylate
- 8.3.2. Non-stimulants
  - 8.3.2.1. Atomoxetine
  - 8.3.2.2. Bupropion
  - 8.3.2.3. Guanfacine
  - 8.3.2.4. Clonidine
8.4. Market Attractiveness Analysis By Drug

9. Global Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032, By Age Group

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis, By Age Group, 2019-2024
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Age Group, 2025-2032
- 9.3.1. Pediatric and Adolescent
- 9.3.2. Adults
9.4. Market Attractiveness Analysis By Age Group

10. Global Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032, By Distribution Channel

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2024
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2025-2032
- 10.3.1. Specialty Clinics
- 10.3.2. Hospital Pharmacies
- 10.3.3. Retail Pharmacies
- 10.3.4. E-Commerce
10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032, By Region

11.1. Introduction
11.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2024
11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
- 11.3.1. North America
- 11.3.2. Latin America
- 11.3.3. Europe
- 11.3.4. East Asia
- 11.3.5. South Asia
- 11.3.6. Oceania
- 11.3.7. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region

12. North America Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032

12.1. Introduction
12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2024
12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
- 12.3.1. By Country
  - 12.3.1.1. U.S.
  - 12.3.1.2. Canada
- 12.3.2. By Drug
- 12.3.3. By Age Group
- 12.3.4. By Distribution Channel
12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Drug
- 12.4.3. By Age Group
- 12.4.4. By Distribution Channel
12.5. Market Trends
12.6. Drivers and Restraints - Impact Analysis
12.7. Key Players - Intensity Mapping
12.8. Country Level Analysis & Forecast
- 12.8.1. U.S. Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 12.8.1.1. Introduction
  - 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.1.2.1. By Drug
    - 12.8.1.2.2. By Age Group
    - 12.8.1.2.3. By Distribution Channel
- 12.8.2. Canada Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 12.8.2.1. Introduction
  - 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.2.2.1. By Drug
    - 12.8.2.2.2. By Age Group
    - 12.8.2.2.3. By Distribution Channel

13. Latin America Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032

13.1. Introduction
13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2024
13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
- 13.3.1. By Country
  - 13.3.1.1. Mexico
  - 13.3.1.2. Brazil
  - 13.3.1.3. Argentina
  - 13.3.1.4. Rest of Latin America
- 13.3.2. By Drug
- 13.3.3. By Age Group
- 13.3.4. By Distribution Channel
13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Drug
- 13.4.3. By Age Group
- 13.4.4. By Distribution Channel
13.5. Market Trends
13.6. Drivers and Restraints - Impact Analysis
13.7. Key Players - Intensity Mapping
13.8. Country Level Analysis & Forecast
- 13.8.1. Mexico Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 13.8.1.1. Introduction
  - 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.1.2.1. By Drug
    - 13.8.1.2.2. By Age Group
    - 13.8.1.2.3. By Distribution Channel
- 13.8.2. Brazil Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 13.8.2.1. Introduction
  - 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.2.2.1. By Drug
    - 13.8.2.2.2. By Age Group
    - 13.8.2.2.3. By Distribution Channel
- 13.8.3. Argentina Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 13.8.3.1. Introduction
  - 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.3.2.1. By Drug
    - 13.8.3.2.2. By Age Group
    - 13.8.3.2.3. By Distribution Channel

14. Europe Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032

14.1. Introduction
14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2024
14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
- 14.3.1. By Country
  - 14.3.1.1. Germany
  - 14.3.1.2. Italy
  - 14.3.1.3. France
  - 14.3.1.4. U.K.
  - 14.3.1.5. Spain
  - 14.3.1.6. BENELUX
  - 14.3.1.7. Russia
  - 14.3.1.8. Rest of Europe
- 14.3.2. By Drug
- 14.3.3. By Age Group
- 14.3.4. By Distribution Channel
14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Drug
- 14.4.3. By Age Group
- 14.4.4. By Distribution Channel
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Key Players - Intensity Mapping
14.8. Country Level Analysis & Forecast
- 14.8.1. Germany Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 14.8.1.1. Introduction
  - 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.1.2.1. By Drug
    - 14.8.1.2.2. By Age Group
    - 14.8.1.2.3. By Distribution Channel
- 14.8.2. Italy Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 14.8.2.1. Introduction
  - 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.2.2.1. By Drug
    - 14.8.2.2.2. By Age Group
    - 14.8.2.2.3. By Distribution Channel
- 14.8.3. France Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 14.8.3.1. Introduction
  - 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.3.2.1. By Drug
    - 14.8.3.2.2. By Age Group
    - 14.8.3.2.3. By Distribution Channel
- 14.8.4. U.K. Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 14.8.4.1. Introduction
  - 14.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.4.2.1. By Drug
    - 14.8.4.2.2. By Age Group
    - 14.8.4.2.3. By Distribution Channel
- 14.8.5. Spain Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 14.8.5.1. Introduction
  - 14.8.5.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.5.2.1. By Drug
    - 14.8.5.2.2. By Age Group
    - 14.8.5.2.3. By Distribution Channel
- 14.8.6. BENELUX Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 14.8.6.1. Introduction
  - 14.8.6.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.6.2.1. By Drug
    - 14.8.6.2.2. By Age Group
    - 14.8.6.2.3. By Distribution Channel
- 14.8.7. Russia Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 14.8.7.1. Introduction
  - 14.8.7.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.7.2.1. By Drug
    - 14.8.7.2.2. By Age Group
    - 14.8.7.2.3. By Distribution Channel

15. East Asia Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032

15.1. Introduction
15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2024
15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
- 15.3.1. By Country
  - 15.3.1.1. China
  - 15.3.1.2. Japan
  - 15.3.1.3. South Korea
- 15.3.2. By Drug
- 15.3.3. By Age Group
- 15.3.4. By Distribution Channel
15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Drug
- 15.4.3. By Age Group
- 15.4.4. By Distribution Channel
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Key Players - Intensity Mapping
15.8. Country Level Analysis & Forecast
- 15.8.1. China Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 15.8.1.1. Introduction
  - 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.1.2.1. By Drug
    - 15.8.1.2.2. By Age Group
    - 15.8.1.2.3. By Distribution Channel
- 15.8.2. Japan Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 15.8.2.1. Introduction
  - 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.2.2.1. By Drug
    - 15.8.2.2.2. By Age Group
    - 15.8.2.2.3. By Distribution Channel
- 15.8.3. South Korea Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 15.8.3.1. Introduction
  - 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.3.2.1. By Drug
    - 15.8.3.2.2. By Age Group
    - 15.8.3.2.3. By Distribution Channel

16. South Asia Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032

16.1. Introduction
16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2024
16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
- 16.3.1. By Country
  - 16.3.1.1. India
  - 16.3.1.2. Indonesia
  - 16.3.1.3. Malaysia
  - 16.3.1.4. Thailand
  - 16.3.1.5. Rest of South Asia
- 16.3.2. By Drug
- 16.3.3. By Age Group
- 16.3.4. By Distribution Channel
16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Drug
- 16.4.3. By Age Group
- 16.4.4. By Distribution Channel
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Key Players - Intensity Mapping
16.8. Country Level Analysis & Forecast
- 16.8.1. India Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 16.8.1.1. Introduction
  - 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.1.2.1. By Drug
    - 16.8.1.2.2. By Age Group
    - 16.8.1.2.3. By Distribution Channel
- 16.8.2. Indonesia Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 16.8.2.1. Introduction
  - 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.2.2.1. By Drug
    - 16.8.2.2.2. By Age Group
    - 16.8.2.2.3. By Distribution Channel
- 16.8.3. Malaysia Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 16.8.3.1. Introduction
  - 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.3.2.1. By Drug
    - 16.8.3.2.2. By Age Group
    - 16.8.3.2.3. By Distribution Channel
- 16.8.4. Thailand Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 16.8.4.1. Introduction
  - 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.4.2.1. By Drug
    - 16.8.4.2.2. By Age Group
    - 16.8.4.2.3. By Distribution Channel

17. Oceania Attention Deficit Hyperactivity Disorder Therapeutics Market 2019-2024 and Forecast 2025-2032

17.1. Introduction
17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2024
17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
- 17.3.1. By Country
  - 17.3.1.1. Australia
  - 17.3.1.2. New Zealand
- 17.3.2. By Drug
- 17.3.3. By Age Group
- 17.3.4. By Distribution Channel
17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Drug
- 17.4.3. By Age Group
- 17.4.4. By Distribution Channel
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Key Players - Intensity Mapping
17.8. Country Level Analysis & Forecast
- 17.8.1. Australia Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 17.8.1.1. Introduction
  - 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.1.2.1. By Drug
    - 17.8.1.2.2. By Age Group
    - 17.8.1.2.3. By Distribution Channel
- 17.8.2. New Zealand Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 17.8.2.1. Introduction
  - 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.2.2.1. By Drug
    - 17.8.2.2.2. By Age Group
    - 17.8.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Attention Deficit Hyperactivity Disorder Therapeutics Outlook, 2019-2032

18.1. Introduction
18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2024
18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2025-2032
- 18.3.1. By Country
  - 18.3.1.1. GCC Countries
  - 18.3.1.2. Turkey
  - 18.3.1.3. North Africa
  - 18.3.1.4. South Africa
  - 18.3.1.5. Rest of Middle East and Africa
- 18.3.2. By Drug
- 18.3.3. By Age Group
- 18.3.4. By Distribution Channel
18.4. Market Attractiveness Analysis
- 18.4.1. By Country
- 18.4.2. By Drug
- 18.4.3. By Age Group
- 18.4.4. By Distribution Channel
18.5. Market Trends
18.6. Drivers and Restraints - Impact Analysis
18.7. Key Players - Intensity Mapping
18.8. Country Level Analysis & Forecast
- 18.8.1. GCC Countries Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 18.8.1.1. Introduction
  - 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.1.2.1. By Drug
    - 18.8.1.2.2. By Age Group
    - 18.8.1.2.3. By Distribution Channel
- 18.8.2. Turkey Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 18.8.2.1. Introduction
  - 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.2.2.1. By Drug
    - 18.8.2.2.2. By Age Group
    - 18.8.2.2.3. By Distribution Channel
- 18.8.3. South Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 18.8.3.1. Introduction
  - 18.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.3.2.1. By Drug
    - 18.8.3.2.2. By Age Group
    - 18.8.3.2.3. By Distribution Channel
- 18.8.4. North Africa Attention Deficit Hyperactivity Disorder Therapeutics Market Analysis
  - 18.8.4.1. Introduction
  - 18.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 18.8.4.2.1. By Drug
    - 18.8.4.2.2. By Age Group
    - 18.8.4.2.3. By Distribution Channel

19. Market Structure Analysis

19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Presence Analysis

20. Competition Analysis

20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Competition Deep Dive
- 20.3.1. Pfizer Inc.
  - 20.3.1.1. Overview
  - 20.3.1.2. Product Portfolio
  - 20.3.1.3. Sales Footprint
  - 20.3.1.4. Key Financials
  - 20.3.1.5. SWOT Analysis
  - 20.3.1.6. Strategy Overview
- 20.3.2. Eli Lilly and Company
  - 20.3.2.1. Overview
  - 20.3.2.2. Product Portfolio
  - 20.3.2.3. Sales Footprint
  - 20.3.2.4. Key Financials
  - 20.3.2.5. SWOT Analysis
  - 20.3.2.6. Strategy Overview
- 20.3.3. Novartis AG
  - 20.3.3.1. Overview
  - 20.3.3.2. Product Portfolio
  - 20.3.3.3. Sales Footprint
  - 20.3.3.4. Key Financials
  - 20.3.3.5. SWOT Analysis
  - 20.3.3.6. Strategy Overview
- 20.3.4. GlaxoSmithKline PLC
  - 20.3.4.1. Overview
  - 20.3.4.2. Product Portfolio
  - 20.3.4.3. Sales Footprint
  - 20.3.4.4. Key Financials
  - 20.3.4.5. SWOT Analysis
  - 20.3.4.6. Strategy Overview
- 20.3.5. Mallinckrodt Pharmaceuticals
  - 20.3.5.1. Overview
  - 20.3.5.2. Product Portfolio
  - 20.3.5.3. Sales Footprint
  - 20.3.5.4. Key Financials
  - 20.3.5.5. SWOT Analysis
  - 20.3.5.6. Strategy Overview
- 20.3.6. Hisamitsu Pharmaceutical Co., Inc.
  - 20.3.6.1. Overview
  - 20.3.6.2. Product Portfolio
  - 20.3.6.3. Sales Footprint
  - 20.3.6.4. Key Financials
  - 20.3.6.5. SWOT Analysis
  - 20.3.6.6. Strategy Overview
- 20.3.7. Johnson & Johnson
  - 20.3.7.1. Overview
  - 20.3.7.2. Product Portfolio
  - 20.3.7.3. Sales Footprint
  - 20.3.7.4. Key Financials
  - 20.3.7.5. SWOT Analysis
  - 20.3.7.6. Strategy Overview
- 20.3.8. UCB S.A.
  - 20.3.8.1. Overview
  - 20.3.8.2. Product Portfolio
  - 20.3.8.3. Sales Footprint
  - 20.3.8.4. Key Financials
  - 20.3.8.5. SWOT Analysis
  - 20.3.8.6. Strategy Overview
- 20.3.9. Purdue Pharma L.P.
  - 20.3.9.1. Overview
  - 20.3.9.2. Product Portfolio
  - 20.3.9.3. Sales Footprint
  - 20.3.9.4. Key Financials
  - 20.3.9.5. SWOT Analysis
  - 20.3.9.6. Strategy Overview